BGM Group Ltd. (BGM)
NEGATIVEFundamental
~22
Price
$0.27
Market Cap
$100M
Part 1 · What the company is worth
Overview
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Limited financial data available (37% of metrics). Scores may not accurately reflect this company's fundamentals.
Balance Sheet & Liquidity
Revenue
$74M
Net Income
$-39M
Free Cash Flow
-
Total Equity
$742M
Total Liabilities
-
Current Ratio
1.24
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$0.10
Current Price
$0.27
Margin of Safety
-165.0%
Fair Value Range
$0.08 - $0.13
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-7.0%
P/B Ratio
0.15
P/FCF
31.32
Gross Margin
16.6%
ROIC
-1.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-1.8%
WACC
14.5%
ROIC − WACC
-16.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (2)
- P/B Ratio 0.15
- Current Ratio
Failed (8)
- Price CAGR -54.38%
- ROIC -1.8%
- Gross Margin 16.6%
- P/FCF 31.32
- DCF valuation (Overvalued)
- ROE -7.0%
- Revenue Growth 5Y -5.4%
- Piotroski F-Score 0/9
Unavailable (17)
- EPS data insufficient
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (need 2+ years)
- Net Margin Trend (invalid data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Ms. Huandi Zhao | Co-Chief Executive Officer & Director | 40 |
| Ms. Li Hong | Co-Chief Executive Officer | - |
| Ms. Yaxuan Zhai | Chief Financial Officer | 30 |
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for BGM, sourced from Markets Gazette.